Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain
Launched by DAEWON PHARMACEUTICAL CO., LTD. · Jul 17, 2017
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • both male and female who are over 19-year-old
- • patient whose pain scale is 4\~9
- • patient who has pain of mononeuropathy
- Exclusion Criteria:
- • patient whose CCr is \<60ml/min
- • patient who has other pain which is not from mononeuropathy
- • patient who is going to have an operation during this study
- • patient who has abnormal ECG
About Daewon Pharmaceutical Co., Ltd.
Daewon Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company dedicated to the development and commercialization of innovative healthcare solutions. With a strong focus on research and development, Daewon specializes in a diverse range of therapeutic areas, including oncology, cardiovascular, and central nervous system disorders. The company is committed to enhancing patient outcomes through high-quality products and clinical trials that adhere to rigorous regulatory standards. By leveraging advanced technologies and fostering strategic partnerships, Daewon Pharmaceutical aims to contribute significantly to global health advancements and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials